PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11929332-5	2002	Treatment for 8 weeks with candesartan cilexetil 16 mg/hydrochlorothiazide 12.5 mg or candesartan cilexetil 16 mg induced SBP/DBP reductions of 12.0/7.5 mm Hg and 7.5/5.5mm Hg, respectively (p < 0.05 both comparisons).	candesartan	27-38	D-box binding PAR bZIP transcription factor	Homo sapiens	126-129	
20016523-3	2010	The objective of this analysis was to compare the efficacy of candesartan and losartan with respect to reduction in systolic and diastolic BP (SBP and DBP).	candesartan	62-73	D-box binding PAR bZIP transcription factor	Homo sapiens	151-154	
20860416-3	2010	Therapy with candesartan cilexetil 0.05, 0.20, and 0.40 mg/kg/day for 4 weeks was effective in the treatment of hypertension in children aged 1 to <6 years, inducing significant dose-dependent reductions from baseline in sitting SBP (SSBP) [primary endpoint] and sitting DBP (SDBP) in the double-blind phase of a randomized, parallel-group, multinational, dose-ranging clinical study.	candesartan	13-24	D-box binding PAR bZIP transcription factor	Homo sapiens	274-277	
12946547-9	2003	Significant changes from baseline to month 12 occurred with candesartan in SBP and DBP (both P < 0.01) and AER (P < 0.05).	candesartan	60-71	D-box binding PAR bZIP transcription factor	Homo sapiens	83-86	
12946547-11	2003	When we interrupted perindopril and candesartan therapy for a 1-month washout period, changes in SBP and DBP values were significant compared with month 12 in both groups (all P < 0.05).	candesartan	36-47	D-box binding PAR bZIP transcription factor	Homo sapiens	105-108	
19090875-3	2008	Systolic (SBP)/diastolic (DBP) blood pressure declined 8.6/4.8-11.2/8.0 mm Hg with candesartan and 3.7/1.8 mm Hg with placebo (P<.01 compared to placebo for SBP and for the mid and high doses for DBP; placebo-corrected 4.9/3.0-7.5/6.2 mm Hg).	candesartan	83-94	D-box binding PAR bZIP transcription factor	Homo sapiens	26-29